N-[4-(trifluoromethyl)phenyl]-4-pyridinecarboxamide | 717858-97-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[4-(trifluoromethyl)phenyl]-4-pyridinecarboxamide
• 英文别名: N-[4-(trifluoromethyl)phenyl]pyridine-4-carboxamide
• CAS: 717858-97-4
• 化学式: C₁₃H₉F₃N₂O
• mdl: MFCD04583067
• 分子量: 266.222
• InChiKey: JFCDNQVJUVAQQQ-UHFFFAOYSA-N

物化性质

• 沸点：
  275.9±40.0 °C(Predicted)
• 密度：
  1.364±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-[4-(trifluoromethyl)phenyl]-4-pyridinecarboxamide 在 sodium tetrahydroborate 、 1-氯乙基氯甲酸酯 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 DMF (N,N-dimethyl-formamide) 、 1,1-二氯乙烷 为溶剂， 反应 47.25h， 生成 1-(3-nitropyridin-2-yl)-N-[4-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine-4-carboxamide
  参考文献：
  名称：

  WO2005/4866

  摘要：

  公开号：
• 作为产物：
  描述：

  异烟酸 、 对三氟甲基苯胺 在 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以35%的产率得到N-[4-(trifluoromethyl)phenyl]-4-pyridinecarboxamide
  参考文献：
  名称：

  Pyridinium cationic-dimer antimalarials, unlike chloroquine, act selectively between the schizont stage and the ring stage of Plasmodium falciparum

  摘要：

  Malaria is a leading cause of death in developing countries, and the emergence of strains resistant to the main therapeutic agent, chloroquine, has become a serious problem. We have developed cationic-dimer type antimalarials, MAP-610 and PMAP-H10, which are structurally different from chloroquine. In this study, we introduced several substituents on the terminal phenyl rings of PMAP-H10. The electronic and hydrophobic properties of the substituents were correlated with the antimalarial activity and cytotoxicity of the compounds, respectively. Studies with synchronized cultures of malarial plasmodia showed that our cationic-dimers act selectively between the schizont stage and the ring stage of the parasitic cycle, unlike chloroquine, which has a stage-independent action. Thus, the mechanism of action of our antimalarials appears to be different from that of chloroquine, and our compounds may be effective against chloroquine-resistant strains. (C) 2008 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2008.04.051

文献信息

• Rhodium(iii)-catalyzed oxidative mono- and di-olefination of isonicotinamides
  作者：Xiaohong Wei、Feng Wang、Guoyong Song、Zhengyin Du、Xingwei Li

  DOI：10.1039/c2ob25773d

  日期：——

  [RhCp*Cl2]2 can catalyze the oxidative coupling of secondary isonicotinamides with activated olefins using Cu(OAc)2 as an oxidant. The selectivity can be controlled by the solvent. In MeCN, the mono-olefination and two-fold oxidation reaction is the major pathway, while in THF this reaction gave mostly diolefination products. In both cases, the coupled products contain an exocyclic CC bond.

  [RhCp*Cl2]2能催化次异烟酰胺与活泼烯烃的氧化偶联反应，以Cu(OAc)2作为氧化剂。通过溶剂可以选择性地控制反应。在乙腈中，单烯化与双氧化反应是主要途径，而在四氢呋喃中该反应主要得到二烯化产物。两种情况下，偶联产物都含有一个环外碳碳键。
• Pd0/PR3-Catalyzed Arylation of Nicotinic and Isonicotinic Acid Derivatives
  作者：Masayuki Wasa、Brady T. Worrell、Jin-Quan Yu

  DOI：10.1002/anie.200906104

  日期：——

  Intermolecular CH functionalization of pyridine rings at the 3‐ and 4‐positions is described using a Pd0/PR3/ArBr catalytic system. This reaction provides a powerful method for the preparation of structurally diverse nicotinic and isonicotinic acids that are of great importance in drug discovery.

  有益于您的健康：使用 Pd 0 /PR 3 /ArBr 催化系统描述了 3 位和 4 位吡啶环的分子间 C  H 官能化。该反应为制备结构多样的烟酸和异烟酸提供了一种强有力的方法，这些酸和异烟酸在药物发现中具有重要意义。
• Therapeutic agents useful for treating pain
  申请人：Kyle J. Donald

  公开号：US20070027159A1

  公开（公告）日：2007-02-01

  A compound of formula: wherein Ar 1 , Ar 2 , V, X, R 3 , R 4 , and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Cyclo(hetero)alkenyl Compound”); compositions comprising an effective amount of a Cyclo(hetero)alkenyl Compound; and methods for treating or preventing, e.g., pain, UI, an ulcer, IBD, or IBS in an animal, comprising administering to an animal in need thereof an effective amount of a Cyclo(hetero)alkenyl Compound are disclosed herein.

  本文披露了一种化合物，其分子式为：其中Ar1、Ar2、V、X、R3、R4和m如本文所述或其药学上可接受的盐（“环（杂）烯基化合物”）；包含有效量的环（杂）烯基化合物的组合物；以及治疗或预防动物的疼痛、尿失禁、溃疡、炎症性肠病或肠易激综合征等疾病的方法，包括向需要的动物中投与有效量的环（杂）烯基化合物。
• THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN
  申请人：Kyle Donald J.

  公开号：US20110152324A1

  公开（公告）日：2011-06-23

  A compound of formula: wherein Ar 1 , Ar 2 , V, X, R 3 , R 4 , and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Cyclo(hetero)alkenyl Compound”); compositions comprising an effective amount of a Cyclo(hetero)alkenyl Compound; and methods for treating or preventing, e.g., pain, UI, an ulcer, IBD, or IBS in an animal, comprising administering to an animal in need thereof an effective amount of a Cyclo(hetero)alkenyl Compound are disclosed herein.

  本文披露了一种化合物，其化学式为：其中Ar1，Ar2，V，X，R3，R4和m如本文所述，或其药物可接受的盐（“环（杂）烯基化合物”）；包含有效量的环（杂）烯基化合物的组合物；以及治疗或预防动物的疼痛、尿失禁、溃疡、炎症性肠病或肠易激综合征等疾病的方法，包括向需要治疗的动物投与有效量的环（杂）烯基化合物。
• Therapeutic Agents Useful for Treating Pain
  申请人：Kyle Donald J.

  公开号：US20130012541A1

  公开（公告）日：2013-01-10

  A compound of formula: wherein Ar 1 , Ar 2 , V, X, R 3 , R 4 , and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Cyclo(hetero)alkenyl Compound”); compositions comprising an effective amount of a Cyclo(hetero)alkenyl Compound; and methods for treating or preventing, e.g., pain, UI, an ulcer, IBD, or IBS in an animal, comprising administering to an animal in need thereof an effective amount of a Cyclo(hetero)alkenyl Compound are disclosed herein.

  本文介绍了一种化合物，其化学式为：其中Ar1，Ar2，V，X，R3，R4和m如本文所述或其药学上可接受的盐（“环（杂）烯基化合物”）; 包含有效量的环（杂）烯基化合物的组合物; 以及治疗或预防动物的疼痛，UI，溃疡，IBD或IBS的方法，包括向需要的动物施用有效量的环（杂）烯基化合物。